Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Tri-NAb for colon cancer treatment

PROVIDER: PRJNA1028345 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26390465_1.fastq.gz	Fastqsanger.gz
	SRR26390465_2.fastq.gz	Fastqsanger.gz
	SRR26390466_1.fastq.gz	Fastqsanger.gz
	SRR26390466_2.fastq.gz	Fastqsanger.gz
	SRR26390467_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Targeting gut microbiota in Kras wild-type and G12D mutated pancreatic cancer mice

Project description:FastQ files from 16S sequencing of fecal samples from pancreatic cancer xenografted mice not treated (CTRL) and treated with chemotherapy (GEM+nab-PTX), probiotics (PRO) and chemotherapy + probiotics (GEM+nab-PTX+PRO)

2024-09-14 | E-MTAB-12171 | biostudies-arrayexpress

The post-biotic sodium butyrate synergizes the antiproliferative effects of dexamethasone against the AGS gastric adenocarcinoma cell

Project description:This research explores the antiproliferative effects of short-chain fatty acid (SCFA) salts (magnesium acetate, sodium propionate, and sodium butyrate) on AGS gastric adenocarcinoma cells. Sodium butyrate (NaB) exhibited the most significant inhibitory impact. The study investigated synergistic interactions between NaB and the drug dexamethasone (Dex) using a combination index model. Dex and NaB at a 2:8 ratio showed strong synergy, surpassing mono treatments in inhibitory activity. NaB induced pro-oxidative effects, countered by Dex in combination. Cell population analyses indicated a shift towards apoptosis with Dex, NaB, and their combination. Proteomic analysis revealed downregulation of the oncogene TNS4, suggesting a potential mechanism for antiproliferative effects. These findings suggest NaB as a potential adjuvant therapy with Dex, prompting further exploration of combination therapies and molecular mechanisms, emphasizing the potential application of these postbiotics in gastric cancer treatment.

2024-02-21 | PXD048617 | Pride

Identification of Predictive Factors in Advanced Pancreatic Cancer Through Extracellular Vesicle Analysis

Project description:The goal of this study is to find a molecular signature that can predict response or resistance to Gemcitabine + Nab-paclitaxel therapy in pancreatic cancer (PC), to aid treatment selection for each patient. To this end, we analyzed blood-derived extracellular vesicles (EV).

2023-05-22 | GSE213341 | GEO

Colon cancer treatment with BAMLET

Project description:Colon cancer treatment with BAMLET

| PRJNA987579 | ENA

The HDAC Inhibitor Sodium Butyrate Prevents Allergic Rhinitis and Alters lncRNA and mRNA Expression Profiles in the Nasal Mucosa of Mice

Project description:Our previous research confirmed that histone deacetylase inhibitor sodium butyrate (NaB), delivered intranasally, has exhibits therapeutic effects on a mouse model of allergic rhinitis (AR). However, whether it is effective on AR when administered orally and prophylactically, as well as its potential effects on gene expression, remained unknown. Methods: In this study, we investigated the preventive effect of NaB on AR when added to the diet of newly weaned mice and evaluated changes in lncRNA and mRNA expression profiles in the nasal mucosa. Mice were randomly divided into three groups as follows: C group (control group, no treatment), AR group (treated with ovalbumin [OVA]), and NaB+AR group (treated with both OVA and NaB). The NaB+AR group was given NaB in their feed (30 g/kg), whereas the other two groups were fed normal feed from 3 weeks to 6 weeks of age. At 7 weeks of age, OVA administration was initiated to induce AR in the AR and NaB+AR groups. Then, behavioral assessments, western blotting, and gene analysis were performed.

2020-03-23 | GSE140454 | GEO

A whole-genome CRISPR screen identifies the spindle accessory checkpoint as a locus of nab-paclitaxel resistance in pancreatic cancer cells.

Project description:Pancreatic adenocarcinoma is one of the most aggressive and lethal forms of cancer. Chemotherapy is the primary treatment for pancreatic cancer, but resistance to the drugs used remains a major challenge. A genome-wide CRISPR interference and knockout screen in the PANC-1 cell line with the drug nab-paclitaxel has identified a group of spindle assembly checkpoint (SAC) genes that enhance survival in nab-paclitaxel. Knockdown of these SAC genes (BUB1B, BUB3, and TTK) attenuates paclitaxel-induced cell death. Cells treated with the small molecule inhibitors BAY 1217389 or MPI 0479605, targeting the threonine tyrosine kinase (TTK), also enhance survival in paclitaxel. Overexpression of these SAC genes does not affect sensitivity to paclitaxel. These discoveries have helped to elucidate the mechanisms behind paclitaxel cytotoxicity. The outcomes of this investigation may pave the way for a deeper comprehension of the diverse responses of pancreatic cancer to therapies including paclitaxel. Additionally, they could facilitate the formulation of novel treatment approaches for pancreatic cancer.

2024-03-21 | GSE262149 | GEO

Alphanudivirus tertidromelanogasteris

Project description:LpEVs treatment of colon cancer cells

| PRJNA943340 | ENA

c-Myc drives nab-paclitaxel resistance in pancreatic cancer

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and very often, ineffective medical and surgical therapeutic options. The treatment of patients with advanced unresectable PDAC is restricted to systemic chemotherapy, a therapeutic intervention to which most eventually develop resistance. Recently, nab-paclitaxel has been added to the arsenal of first line therapies, and the combination of gemcitabine and nab-paclitaxel has modestly prolonged median overall survival. However, patients almost invariably succumb to the disease, and little is known about the mechanisms underlying nab-paclitaxel (n-PTX) resistance. Using the conditionally reprogrammed (CR) cell approach, we established and verified continuously growing cell cultures from treatment-naive PDAC patients. To study the mechanisms of primary drug resistance, nab-paclitaxel-resistant (n-PTX-R) cells were generated from primary cultures and drug resistance was verified in vivo, both in zebrafish and in athymic nude mouse xenograft models. Molecular analyses identified the sustained induction of c-MYC in the nab-paclitaxel-resistant cells. Depletion of c-Myc restored nab-paclitaxel sensitivity, as did treatment with either the MEK inhibitor, trametinib, or a small molecule activator of protein phosphatase 2a (SMAP). Implications: The strategies we have devised, including the patient-derived primary cells and the unique drug resistant isogenic cells, are rapid and easily applied in vitro and in vivo platforms to better understand the mechanisms of drug resistance and for defining effective therapeutic options on a patient by patient basis

2019-05-31 | GSE131762 | GEO

RNA-seq analysis of SMARCA4-deficient NCI-H838 xenograft tumors treated with PRT3789, docetaxel, nab-paclitaxel, or combination regimens

Project description:The goal of this study was to examine transcriptional responses to the SMARCA2-selective degrader PRT3789, standard chemotherapies, and their combinations in SMARCA4-deficient NCI-H838 xenograft tumors. Six treatment groups were evaluated: (1) vehicle control, (2) PRT3789, (3) docetaxel, (4) nab-paclitaxel, (5) PRT3789 plus docetaxel, and (6) PRT3789 plus nab-paclitaxel. RNA-seq was performed on tumors collected 120 hours post–first dose to investigate treatment-specific gene expression signatures.

2025-09-12 | GSE307427 | GEO

Cerulenin action on colon cancer cell line

Project description:Showing the anti cancer activity of Cerulenin on colon cancer cell lines. The study shows the mechanismm of apoptosis induction as a result of cerulenin treatment to colon cancer cell lines.

2023-02-05 | PXD023569 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data